Table 2.

FDA-approved DDR inhibitors in breast cancers in the past 5 years (2016–2021)

PARP inhibitors	Trial number	Disease setting	FDA approval	Approved mutation status	Study phase	Approved year
Olaparib	NCT02000622	Metastatic, gBRCA1/2-mutant, HER2-negative breast cancer after ≤ 2 prior lines of chemotherapy	Metastatic, HER2-negative breast cancers	BRCA1/2 mutations	III	2018
Talazoparib	NCT01945775	Advanced and/or metastatic HER2-negative breast cancer with germline BRCA1/2 mutation	HER2-negative locally advanced or metastatic breast cancer	Deleterious or suspected deleterious germline BRCA mutation	III	2018